November 4, 2022

Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline

Concerto Biosciences, a biotechnology company designing microbial communities that restore deficient microbiomes to treat disease, announced today that it raised $23 million in a Series A funding round led by Safar Partners and joined by Horizons Ventures and M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), among others. Representatives from Safar Partners and M Ventures will join the company’s board of directors.

Concerto Biosciences was an awardee of the MLSC’s Angel Investor Tax Credit Program. This program is offered to investors interested in funding early-stage companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts.